John Chan, M.D.

Board-certified in anatomic pathology, clinical pathology and hematology, Dr. Chan is a hematopathologist who came to City of Hope's Toni Stephenson Lymphoma Center from the University of Nebraska Medical Center in Omaha where he was co-director for its Center for Lymphoma and Leukemia Research, and an endowed professor in the Department of Pathology and Microbiology. Previously, he was an associate professor and director of the Hematopathology Training Program and director of Hematology Laboratories at Emory University’s School of Medicine.
 
Dr. Chan is an internationally respected molecular pathologist, who has made numerous significant contributions to the field of pathology and malignant hematology. He is widely published, with more than 340 papers in the peer reviewed literature, over 258 abstracts, and 31 chapters in various textbooks.  He had served as  an associate editor of the American Journal of Pathology and on the editorial board of AJCP.  He has also served in many NIH studies sections and was a member of the Cancer Biomarkers Study Session. Dr. Chan has received numerous research grants for his work, including multiple grants from the NIH/NCI. LLS and LRF. Dr Chan has extensive experience in the genomics investigation of lymphoma and have establishing large multi-institutional consortia of leading lymphoma centers in the world to perform large scale studies to provide insight into the pathogenesis, prognosis and treatment of lymphoma, and to generate hypothesis for further studies. His consortia have been highly productive and aside from published reports, have generated large gene expression profiling, genetic, and microRNA data bases as well as associated tissue and clinical resources for further studies. T and NK-cell lymphomas have been his area of focus for the past 8 years and his lab has performed in-depth studies on a number of key driver mutations. His lab also has extensive experience in genetically modifying normal human lymphocytes for functional investigations. Ongoing projects include:

1P01CA229100-01
Molecular Diagnosis, Prognosis, and Therapeutic Targets in Lymphoma;  Rimsza (PI)
Role: Co-PI  (Iqbal/Chan)
09/19/2018 – 08/31/2023
Project 3 - Molecular Pathogenesis of two newly defined major subgroups of PTCL 

1UH2/UH3CA206127-01A1                                    
Chan/Iqbal (Multi-PI)
04/01/2017 – 03/31/2022
Molecular diagnostic and prognostic signatures for PTCL

2P50CA107399-11A1            
Forman/Kwak (Multi-PI); Role: Biospecimen Core Director; Co-Director of the Developmental Research Program (with Dr. Kwak) 
09/01/2018 – 08/31/2023 
City of Hope Lymphoma SPORE     

MCL SCOR 7000-18, The Leukemia Lymphoma Society:
Kwak (PI); Role:  Chan (Core Leader)
01/01/2018 – 12/31/2022
Delivering Unique Immunotherapies for Treatment of Mantle Cell Lymphoma.  

1 P01 CA233412-01A1 
Targetable Vulnerabilities in Peripheral T-cell Lymphomas; (Overall PI: David Weinstock)Multi PI: Markus Müschen and Wing Chan
09/01/2019 – 08/31/2024
Project 1: Targeting Oncogenic TCR Signaling in PTCL,

NCI RO1  PA18-484 Multi-PI: Iqbal/Chan  
8-1-21 TO 7-31-26     
Concurrent TET2 and IDH2 mutations in the pathogenesis of Angioimmunoblastic T-Cell Lymphoma. 

U01CA253218;                        
Multi-PI Iqbal/Chan/Murtaza                                                     
09/20/2021 – 08/31/2026               
Pre-analytical variables of bioanalytes affecting the accuracy of PTCL diagnostic and prognostic genetic signatures.

DoD W81XWH-21-PRCRP-TTSA
Multi-PI  IQBAL j/Chan, W.C
07/012022 – 06/30/2027
Genomic biomarker driven treatment strategy for peripheral T-cell lymphoma

He has been invited to speak at over 100 national and international conferences and holds active memberships in several professional societies.